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ABSTRACT 
INFLAMMATORY CELL TUMOR NECROSIS FACTOR SIGNALING 
MODULATES POST-INFARCTION LEFT VENTRICULAR REMODELING 
Robert Kenneth Lewis 
December, 2010 
The fundamental question of the exact nature of the role played by TNF in the 
failing myocardium remains one of contention. Many preclinical studies have 
demonstrated beneficial effects with TNF antagonism and recently the 
dichotomous role played by the two TNF receptors in chronic ischemic injury has 
come to light. The failing heart has also been determined to have low levels of 
inflammatory cell infiltration. As these cells are known to be potent producers of 
inflammatory cytokines, we hypothesized that inflammatory cell localized TNF 
receptors play an important role in the progression of LV remodeling following 
ischemic injury. To isolate the in vivo effects of inflammatory cell TNF receptors, 
we generated chimeric mice. Wild-type (WT, C57BLl6) mice underwent radiation-
induced bone marrow (BM) ablation followed by reconstitution with BM from WT 
mice (WTc control, n=30), TNFR 1-/- mice (R1-/-c, n = 30) or TNFR2 -/- mice 
(R2-/-c, n = 30). Six weeks later, WTc, R1-/-c, and R2-/-c mice were subjected to 
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coronary ligation to induce heart failure (HF) or sham operation. Our results 
demonstrated that compared to WTc sham, 4 weeks after surgery, WTc HF 
hearts exhibited significantly (p < O.OS): 1) increased LV size (EDV 96.7 ±. 13.7 
vs. 26.6 ± 8.2 IJL) and dysfunction (LVEF 2S.S ± 7.S vs. 69.8 ± 4.S%); 2) greater 
hypertrophy (LV/tibia length [TL] 3.91 ± 0.S3 vs. 2.9 ± 0.4, -4-fold greater atrial 
natriuretic factor [ANF] mRNA); 3) increased fibrosis (16.10 ± 8.16% vs. 1.4 ± 
0.4%) and connective tissue growth factor (CTGF) mRNA expression, and 4) 
increased (-2-fold) mRNA levels of TNF, interleukin (IL)-1j3, and IL-6. WTc HF 
mice also had markedly reduced survival (60% vs. 100%) and increased blood 
levels of activated F4/80+/CD11 b+ monocytes vs. WTc sham mice. In contrast, 
compared to WTc HF, R1-1-c HF mice exhibited significantly (p < O.OS): 1) 
improved survival (80%), 2) less LV dilatation and improved LVEF (42.9 ± 4.2%), 
3) less cardiac hypertrophy (LVITL 3.14 ± 0.2) and ANF mRNA expression, 4) 
less cardiac fibrosis (S.48 ± 2.26%) and CTGF mRNA expression, and S) less 
cardiac TNF and IL-1j3 mRNA expression. Also, compared to WTc HF, R2-/-c HF 
mice exhibited significantly (p < O.OS) greater circulating F4/80+/CD11 b+ 
monocytes (1S.32 ± 4.41 vs. 12.1 ±1.24%), and greater cardiac fibrosis (21.92 ±. 
10.81%). Also noted was an increase, although not significant, in EDV and ESV. 
In parallel in vitro studies, the contribution of inflammatory cell TNFR1 and 
TNFR2 (Le., macrophage-derived) to cardiac contractile dysfunction was 
investigated. Macrophages isolated from WT mice with HF 4 week post-
infarction, when co-cultured with na"lve cardiomyocytes induced contractile 
dysfunction and myocyte reactive oxygen species (ROS) generation in a 
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juxtacrine but not paracrine maner (p<O.001). Interestingly the effect on 
contractile dysfunction was diminished with the loss of TNFR1 in the HF 
macrophages but remained unchanged upon loss of TNFR2. Of note, ROS 
production in these groups followed a similar pattern in that loss of TNFR1 
resulted in significantly attenuated myocyte ROS production upon HF 
macrophage contact with na"lve myocytes. We therefore conclude that 
inflammatory cell-localized TNF receptor signaling has fundamental yet 
dichotomous, roles in post-infarction LV remodeling. In that inflammatory cell 
TNFR1 is required for the production of the pro-inflammatory state in failing 
myocardium and exacerbates post-infarction remodeling. Moreover, TNFR1 
signaling in macrophages in HF augments macrophage-induced contractile 
dysfunction and ROS generation. Inflammatory cell-localized TNFR2 signaling 
has modest antifibrotic effects in the failing heart. TNF-dependent inflammatory 
cell responses are critical for the progression of pathological remodeling in HF. 
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Several complex pathophysiologic mechanisms influence the process of left 
ventricular (LV) remodeling in chronic heart failure (HF). These include changes 
in mechanical forces, such as wall stress and increases in systemic vascular 
resistance, creating afterload mismatches, inflammatory cytokine production 
particularly TNF, IL-1, and IL-6, and activation of neurohormonal signaling 
pathways, most importantly the renin-angiotensin system and the sympathetic 
nervous system [1-8]. (Figure 1) 
These responses initially help compensate for the acute phase of myocardial 
injury and its physiological consequences. For example, increased salt and fluid 
retention mediated by angiotensin and increases in systemic vascular resistance 
and heart rate driven by the sympathetic nervous system serve to maintain blood 
pressure and cardiac output, facilitating organ perfusion. In the chronic HF state, 
however, these responses become detrimental, creating a milieu that precipitates 
the undesirable consequences of myocyte apoptosis, mitochondrial dysfunction, 
myocyte hypertrophy, and contractile dysfunction [9-12]. This ultimately results 
in LV remodeling grossly evident by chamber dilatation [2-6]. On the molecular 
level, the phenotype of HF includes activation of the fetal gene program [1,13]. 
abnormalities of calcium handling [14-18]. uncoupling of 13-adrenergic receptor 
(l3-AR) signaling [19-21], reactive oxygen species (ROS) production [10,22-26], 
and activation of inflammatory pathways. These pathological changes are 
characteristic phenotypic features of HF, and thus can be used as physiological 
indices of the severity of cardiac dysfunction and remodeling. 
Myocardial Injury 
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I Oxidative Stress I 
Fig1: Pathological mechanisms of LV remodeling after myocardial injury [13] 
As mentioned above, inflammation is a hallmark of chronic HF [27,28]. Elevated 
levels of pro-inflammatory cytokines such as TNF, interlukin-113 (IL-1 A and 
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interlukin-6 (IL-6) are present at high levels in the plasma of HF patients. 
Interestingly, the level of these cytokine correlates inversely with survival [29-31]. 
Moreover, levels of the anti-inflammatory cytokine interleukin-10 (lL-10) have 
been observed to be significantly reduced in chronic HF patients [32-35]. 
Elevated levels of pro-inflammatory cytokines have not only been observed 
systemically but in the injured myocardium as well. Together these findings 




Why would TNF matter in Heart Failure? 
Several lines of evidence point to TNF as a potential target of therapeutic interest 
in chronic HF. First, elevated plasma levels of TNF and IL-6, as well as soluble 
TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2) function as independent 
predictors of mortality in HF patients [31,39,40]. Secondly, in experimental animal 
models, TNF via infusion or over expression, can reproduce many of the 
phenotypic responses noted in HF, specifically depressed contractile function 
[41-43], myocyte hypertrophy [28,44], P-AR uncoupling [43], apoptosis [45], and 
ROS production [46] indicating that TNF in sufficient levels, even in the absence 
of antecedent injury, can decrease myocardial performance. Third, mice with 
cardiac-specific TNF over-expression suffer a premature death with a dilated 
cardiomyopathy, characterized by many of the same pathologic findings seen in 
chronic ischemic HF [47-49]. Fourth, while it is true that several pro-
inflammatory cytokines are up regulated in the setting of HF, TNF is a foundation 
cytokine, that has the ability to modify the expression of others such as IL-1 P and 
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IL-6 [50,51]. Lastly, antagonism of TNF in several animal models including TNF 
infusion [5], cardiac specific TNF over expression [52], and in post infarction HF 
[53-57] ameliorates the deleterious effects of pro-inflammatory milieu seen with 
the preceding conditions. 
Clinical Trials: What Happened? 
The findings of the above mentioned animal studies created a great deal of 
enthusiasm in the HF community. Hurried enthusiasm led to the initiation of 
clinical studies to test the effectiveness of TNF antagonism in chronic HF. Two 
forms of TNF antagonism where used. The first was etanercept, a previously 
FDA-approved drug for use in the chronic inflammatory condition of rheumatoid 
arthritis, consisting of two TNFR2 receptors linked to human IgG1 :Fc. The 
second drug was infliximab, composed of anti-TNF murine Fab linked to human 
IgG1:Fc. This drug was also FDA-approved for human usage prior to the HF 
trials for the same indication as entanercept. The four clinical trials where named 
RECOVER, RENAISSANCE, RENEWAL, AND ATTACH. Each independently 
reached conclusions that put the HF community in flux. Interestingly these trials 
showed no beneficial effect from TNF antagonism and concluded that both 
increased deaths and HF hospitalizations occur in a time and dose dependent 
manner in response to TNF antagonists [28,50,58]. This of course was quite 
surprising given the promising nature of the pre-clinical data, and begged the 
question, why the dichotomous results? Why did the clinical trials prove to be 
such a disappointment? While the true reason is yet undefined, several 
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hypotheses have been proposed [28,50,58] to explain the surprising findings. 
The most popular of the possible explanations is poor study design. While this 
always seems to be the first criticism put forth when things don't go as planned, 
there is likely some validation for this claim. Many investigators argue that these 
trials were plagued by the selection of patients with disease so advanced they 
where unlikely to recover, improper drug dosing both in quantity given and timing, 
and poorly defined end points. A second possible explanation is that the side 
effects of the drugs used were not completely understood, and that some of the 
toxicity observed had nothing to do with myocardial TNF interaction, but was 
related to the inherent pharmacologic properties of the drugs themselves. Lastly 
and perhaps most intriguing is that role of TNF in HF is more complicated and 
diverse than previously believed, and a deeper and more profound 
understanding of the complex and wide ranging interactions of TNF was needed 
before we could understand the proper use of TNF antagonism in chronic HF. 
The complicated nature of TNF 
It is known that TNF, along with other pro-inflammatory cytokines, is an 
evolutionarily well-conserved stress response molecule. From an intuitive 
standpoint, the highly-conserved nature implies an element of usefulness. In the 
myocardium, TNF provides protection during the acute phase of ischemic injury 
[59,60], and during infective myocarditis [61,62]. TNF may have multi-faceted 
effects in the heart that produce either adaptive or maladaptive responses based 
on a delicate balance of cytokine and receptor expression. Previous work, 
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discussed later, has shown that there is a dichotomous effect in the failing 
myocardium that is TNF receptor dependent [63]. 
To fully grasp the effects of TNF, it is important to understand its signaling 
mechanisms. TNF is expressed as both a soluble molecule (sTNF) and in a 
membrane bound form (mTNF) [64-69]. Likewise, TNF signaling occurs through 
two cell surface receptors, TNF receptor 1 (TNFR1) and TNF receptor 2 
(TNFR2). Neither receptor possesses enzymatic activity, and as a result 
signaling involves recruitment of additional intracellular proteins. TNFR1 binding 
and activation results in the recruitment of: 1) TNF receptor associated death 
domain (TRADD) ultimately resulting in the activation of caspase dependent 
apoptosis, and 2) TNF receptor-associated factor 2 (TRAF2) through the TRADD 
leading to the activation of nuclear factor- kappa B (NF-KB), c-Jun N-terminal 
kinase (JNK) phosphorylation leading to activation of activator protein-1 (AP-1), 
and p38 mitogen activated protein kinase (MAPK) activation. There is a 
significant amount of cross talk between the two receptors and their downstream 
signals [64-67]. However, TNFR2 does not bind to the TRADD but instead 
directly activates TRAF2 resulting in the same activation of NF-KB, AP-1, and 
p38 MAPK. (Figure 2) TNFR1 and TNFR2 also differ in their response to the 
different forms of TNF that serves to activate these receptors. Whereas TNFR1 
is activated equally by both sTNF and mTNF forms, TNFR2 is activated 
predominantly by mTNF [64,65,67,70]. Most of the in-vitro studies that define cell 
signaling use sTNF, and under these conditions TNFR2 is not activated to any 
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significant extent. Because of this, TNFR2 intracellular mechanisms are not as 
clear as those of TNFR1, and hence the benefits and consequences of its 
signaling mechanisms are not as well delineated. 
Figure 2: TNFR1 and TNFR2 signaling mechanisms. [66] 
The heart normally expresses equal amounts of TNFR1 and TNFR2. However, 
during the normal homeostatic state, there is no constitutive myocardial 
expression of TNF in either the membrane bound or soluble form [29,71]. In the 
failing heart, however, there is significant expression of TNF and a substantial 
but equal down regulation of both TNF receptors to approximately one-half of 
their constitutive expression [29] . This is, of course, not an uncommon response 
to a dramatic and chronic increase in receptor stimulation. There is also a 
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substantial increase in soluble TNF receptor levels in the serum of HF patients, 
possibly indicating a mechanism by which TNF responses are modulated [29]. 
In vivo, TNF can produce its effects in a juxtracrine manner, i.e. cell-to-cell 
physical contact. These interactions are more dependent on mTNF than the 
soluble form. Moreover, the dichotomy in the functional activation of the two TNF 
receptors in experimental models suggests either mTNF or sTNF over 
expression. In models of cardiac specific mTNF over-expression, resulting in 
primarily TNFR2 activation, concentric hypertrophy LV occurs, whereas in sTNF 
over-expression models, the animals develop a dilated cardiomyopathy [72]. 
Further evidence of divergent phenotypic responses is seen in disease states 
involving organ systems other than the myocardium. In a model of retinal 
ischemia, signaling through TNFR1 results in a worse phenotype [73]. On the 
other hand TNFR2 is primarily responsible for the detrimental effects of TNF in 
inflammatory arthritis as well as inflammatory bowel disease (IBD) [74]. 
Inflammatory cells are the major source of TNF production in the baseline state 
[64]. These cells also serve as an important source of pro-inflammatory 
cytokines during chronic HF, producing significantly elevated levels of TNF [75]. 
There is also progressive macrophage infiltration observed in the failing 
myocardium that positively correlates with disease severity [36,76-80]. 
Furthermore, co-localization of IL-1j3 and TNF occur in these infiltrating cells 
[36,76,78] demonstrating their active nature. These cells not only invade the 
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failing myocardium but are activated, producing pro-inflammatory cytokines and 
exerting detrimental effects in the heart. Furthermore, in an ischemic HF model, 
the administration of an inhibitor of monocyte! macrophage activation 
dramatically reduced myocardial expression of TNF, demonstrating the 
significant contribution of these cells to cardiac TNF production in HF [81]. To 
this point, differential cell-type specific responses occur with cytokine stimulation 
[64,66]. Inflammatory cells release a host of cytotoxic mediators with cytokine 
stimulation [82,83] that may affect adjacent cells [84]. One example is the 
release of nitric oxide (NO) from stimulated macrophages leading to superoxide 
generation and peroxnitrite formation [85-88]. To further support the importance 
of the inflammatory cell's interaction with the heart, studies of endotoxemia show 
that inducible NO synthase (iNOS) from inflam matory cells, and not myocytes, is 
responsible for myocardial dysfunction in sepsis [84,89]. 
Unraveling the mystery 
Previous work in the Prabhu lab further delineate the possibility of a dichotomous 
relationship between the two TNF receptors in chronic HF that is apparent in 
extracardiac disease processes. This work shows that somatic TNFR1 and 
TNFR2 null mice exhibit disparate effects on many of the hallmark phenotypical 
findings in chronic HF, specifically LV remodeling and myocyte hypertrophy, 
when subjected to permanent coronary ligation [63]. 
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To obtain this initial data, TNFR1-/- and TNFR2-/- mice were compared to 
C57BL6 mice after undergoing either permanent left coronary artery ligation to 
induce HF or sham operation. As expected, the C57BL6 mice exhibited 
significant LV dilatation and dysfunction. However, these detrimental effects 
were alleviated in TNFR1-1- mice (unopposed TNFR2 stimulation). Interestingly, 
TNFR2-/- mice (unopposed TNFR1 stimulation) demonstrated an exaggerated 
remodeling response to chronic ischemic injury [63]. 
The above observations suggest that TNFR1 and TNFR2 have divergent effects 
on the pathological remodeling in HF, in that TNFR1 augments and TNFR2 
attenuates this process. Furthermore, as activated inflammatory cells impart 
significant toxic cytokine-mediated responses on adjacent tissues, it is also likely 
that the TNFRs would demonstrate divergent and opposing phenotypic 
responses in HF if modulated in the inflammatory compartment. 
I seek to define an integrated model of TNFRs and activated macrophages in the 
failing myocardium. I propose, as shown in Fig 3, a hypothesis that in activated 
macrophages infiltrating the failing heart, TNFR1 increases whereas TNFR2 
opposes, or at least does not exacerbate, cellular activation as well as toxic 
metabolites and cytokine production. These changes serve to affect, in a 
dichotomous manner based on TNFRs, adjacent myocyte function and LV 




Phenomenon: Several pre-clinical and clinical studies have been undertaken to 
delineate the role of TNF in chronic HF. While the pre-clinical animal studies of 
TNF antagonism have been overwhelmingly positive, the clinical studies with 
TNF antagonist proved not only negative, but demonstrated an increase in 
morbidity and mortality. Hence, the precise role of TNF as a therapeutic target in 
HF remains yet undetermined. 
Proposed concepts: Fundamental questions remain regarding the role of TNF 
in chronic HF. Previously the Prabhu lab demonstrated a dichotomous role for 
TNF in chronic murine HF dependent on the receptor stimulated, TNF receptor 1 
or receptor 2. This could perhaps explain some of the conflicting data observed 
in the pre-{;Iinical and clinical studies. Given, however, that a substantial 
percentage of the TNF produced during an inflammatory state is a product of 
inflammatory celis, and that pro-inflammatory cytokines have been determined to 
playa substantial role in the pathology of HF, it is possible that TNF exhibits both 
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temporal, i.e. early vs. late HF, and spatial, i.e. somatic vs. inflammatory cell 
differences, that further determine the complex nature of TNF in chronic HF. 
Experimental design: To determine the role of TNF in HF, an experimental 
protocol was designed to test the following hypothesis. 
Hypothesis: 
TNF has complex and dichotomous effects based on the TNF receptor 
stimulated. Likewise, inflammatory cells and their products play an 
important and deleterious role in the propagation of the pathology 
associated with chronic HF. I propose that selective modulation of the 
TNFRs in the inflammatory compartment will result in phenotypic 
differences in chronic ischemic heart failure. The ablation of TNFR1 will 
result in beneficial changes and the loss of TNFR2 will serve to further 
worsen the HF phenotype or possibly have no effect, if the primary 
detrimental effects are mediated by TNFR1. (Figure 3) 
Aim #1: To define the in vivo role of the inflammatory cell, as opposed to the 
myocyte, with regards to the divergent TNFR-specific effects in post-infarction LV 
remodeling. 
Aim#2: To delineate the role of the TNF receptor in in vitro macrophage-myocyte 
interactions in the setting of heart failure. 
13 




Figure 3: Graphical representation of the hypothesis for AIM 1. In response to ischemic injury activated 
macrophages infiltrate the myocardium. These macrophages assert their effects in a TNF dependent 
manner based on a dichotomous relationship between TNFR1 and TNFR2. TNFR1 increases whereas 
TNFR2 opposes cellular activation as well as toxic metabolite and cytokine production. These changes 
serve to effect adjacent myocyte function and LV remodeling in response to ischemic injury. 
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CHAPTER IV 
AIM #1: TO DEFINE THE IN VIVO ROLE OF THE INFLAMMATORY CEll, AS 
OPPOSED TO THE MYOCYTE, WITH REGARDS TO THE DIVERGENT TNFR-
SPECIFIC EFFECTS IN POST-INFARCTION lV REMODELING. 
BRIEF PREVIEW 
Background: Elevated myocardial and systemic levels of inflammatory 
mediators are hallmarks of chronic heart failure (HF) and predictors of mortality. 
Tumor necrosis factor-a (TN F), a "foundation" cytokine that influences other 
inflammatory mediators, is considered to play a detrimental role in the 
pathogenesis of LV remodeling. However, large multi-center clinical trials of 
biological anti-TNF therapy in HF have been negative, demonstrating no effects 
or even increased mortality with such therapy. This suggests that the effects of 
TNF are not homogeneous, and are more complex than an all-or-none toxic 
response in the failing heart. TNF signals through two cell-surface receptors, 
TNFR1 and TNFR2. TNF induces divergent inflammatory and remodeling 
responses in the failing heart that are TNF-receptor specific: TNFR1 signaling is 
detrimental and promotes these effects, whereas TNFR2 signaling is beneficial 
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and opposes these effects. Importantly, in addition to myocyte-specific effects, 
TNF also activates immune and inflammatory cells that are potential sources of 
cytokines and cellular toxicity in HF. However, the importance of inflammatory 
cell-localized TNF responses in the pathogenesis of LV remodeling is unknown 
Hypothesis: Inflammatory cell-localized TNFR1 and TNFR2-signaling play 
important and divergent roles in the progression of post-infarction LV remodeling 
in chronic HF. My study objective was to evaluate the effects of selective 
inflammatory/immune cell TNFR1 or TNFR2 ablation on LV remodeling 
Methods: In order to delineate the role of immune cell TNFR1 and TNFR2 in LV 
remodeling chimeric mice were generated. Recipient WT C57BLl6 mice 
underwent lethal bone marrow irradiation followed by reconstitution with bone 
marrow from either TNFR1 -/- or TNFR2 -/- mice. Reconstituted with bone 
marrow from C57BLl6 were used as a control. Mice were quarantined for 30 
days post-transplant to ensure adequate resident cell turnover, and chimerism 
was confirmed via flow cytometery of donor CD45.2 and recipient CD45.1. All 
mice exhibited more than 90% marrow chimerism. Mice were evaluated at 
baseline and sequential time points via echocardiography and flow cytometry. 
Phenotypic assessment with a variety of physiologic, histologic, and molecular 
techniques was performed as discussed in detail in the Methods section. 
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Results: These mice, which exhibit loss of either TNFR1 (R1-/-c) or TNFR2 
(R2-/~) or loss of neither receptor (WTc) in inflammatory cells, underwent 
coronary ligation to induce HF or sham operation. Compared to WTc sham, 4 
weeks after surgery, WTc HF hearts exhibited significantly (p < O.OS): 1) 
increased LV size (EDV 96.7 ±. 13.7 vs. 26.6 ± 8.2 IJL) and dysfunction (LVEF 
2S.S ± 7.S vs. 69.8 ± 4.S %); 2) greater hypertrophy (LV/tibia length [TL] 3.91 ± 
0.S3 vs. 2.9 ± 0.4, -4-fold greater atrial natriuretic factor [ANF] mRNA); 3) 
increased fibrosis (16.10 ± 8.16% vs. 1.4 ± 0.4 %) and connective tissue growth 
factor (CTGF) mRNA expression, and 4) increased (-2-fold) mRNA levels of 
TNF, interleukin (IL)-1~, and IL-6. WTc HF mice also had markedly reduced 
survival (60% vs. 100%) and increased blood levels of activated F4/80+/CD11b+ 
monocytes vs. WTc sham mice. In contrast, compared to WTc HF, R1-/~ HF 
mice exhibited significantly (p < O.OS): 1) improved survival (80%), 2) less LV 
dilatation and improved LVEF (42.9 ± 4.2 %),3) less cardiac hypertrophy (LVITL 
3.14 ± 0.2 mg/mm) and ANF mRNA expression, 4) less fibrosis (S.48 ± 2.26 % 
area) and CTGF mRNA expression, and S) less cardiac TNF and IL-1~ mRNA 
expression. Also, compared to WTc HF, R2-/-c HF mice exhibited significantly (p 
< O.OS) greater circulating F4/80+/CD11 b+ monocytes (1S.32 ± 4.41 vs. 12.1 
±1.24 % gate), and greater cardiac fibrosis (21.92 ±. 10.81 % area). Also noted 
was an increase, although not significant, in EDV and ESV. 
Conclusion: Inflammatory cell-localized TNFR1 signaling exacerbates 
inflammation and cardiac remodeling in HF, whereas inflammatory cell TNFR2 
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signaling has modest anti-fibrotic and anti-inflammatory effects. Modulation of 
global inflammatory cell function induces profound localized alterations in LV 
remodeling; TNFR1/R2 signaling plays an important role in these effects. 
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INTRODUCTION 
It is well established that inflammation is one of the key mediators of the 
deleterious effects seen in chronic HF [27,28]. Elevated levels of pro-
inflammatory cytokines such as TNF are present in the plasma and myocardium 
of HF patients. Interestingly, levels of these cytokines correlate inversely with 
survival in chronic HF [29-31]. Collectively, these findings delineate that there is 
a pro-inflammatory imbalance in chronic HF, and that this imbalance plays a 
substantial role in the progression of disease [29, 36-38]. 
Several lines of evidence point to TNF as a potential target of therapeutic interest 
in chronic HF. First, as mentioned above, elevated plasma levels of TNF 
function as independent predictors of mortality in HF patients [31,39,40]. 
Secondly, in experimental animal models, TNF infusion or over-expression 
reproduces many of the phenotypic responses noted in HF [28,41-46]. Also, 
TNF has been shown to be a foundation cytokine in that has the ability to modify 
the expression of the other pro-inflammatory cytokines such as IL-113 and IL-6 
[50,51]. Lastly, antagonism of TNF in several animal models, including TNF 
infusion [5], cardiac specific TNF over-expression [52], and in post-infarction HF 
[53-57], ameliorate the deleterious effects of the pro-inflammatory milieu seen in 
these conditions. 
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The above findings led to the initiation of clinical studies of TNF antagonism in 
chronic HF patients. Interestingly these trials not only failed to show beneficial 
effects, but also that TNF antagonism increased death and HF hospitalization in 
a time and dose dependent manner [28, 50]. This of course was quite surprising 
given the robust pre-clinical data showing the very promising possibilities for TNF 
modulation. These results raised the question as to why the clinical trials prove 
to be such a disappointment? Perhaps the role of TNF in HF is more complicated 
and diverse than previously believed. TNF may in fact have multi-faceted effects 
in the heart that can produce either adaptive or maladaptive responses based on 
a delicate balance of cytokine and receptor expression. Previous work has 
proven that in fact there is a dichotomous effect in the failing myocardium which 
is TNF receptor dependent [63]. 
The primary sources of TNF in the quiescent state are monocytes and 
macrophages [64]. Likewise, these cells also serve as an important source of 
pro-inflammatory cytokines in HF, producing significantly elevated levels of TNF 
and other mediators of inflammation [75]. There is progressive macrophage 
infiltration observed in the failing myocardium that positively correlates with 
disease progression [36,77-80]. Furthermore, co-localization of IL-1 ~ and TNF 
has been demonstrated in these infiltrating cells [36,78]. Likewise in an ischemic 
HF model, administration of an inhibitor of monocyte/macrophage activation 
dramatically reduced myocardial expression of TNF, demonstrating the 
significant contribution of these cells to cardiac TNF production in HF [81]. 
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Previous work in our lab has shown that TNFR1 and TNFR2 whole body knock 
out (-1-) animals exhibit disparate effects on post-infarction LV remodeling, 
hypertrophy, inflammation, and apoptosis [63]. This would suggest that TNFR1 
and TNFR2 have divergent effects in HF in regards to the primary responses 
mediated by TNF, namely inflammation and myocardial dysfunction, in that 
TNFR1 augments while TNFR2 attenuates these processes. Furthermore, as 
activated inflammatory cells impart significant toxic cytokine medicated 
responses on adjacent tissues, it is possible that the TNFRs could impart 
analogous divergent and opposing phenotypic responses in HF if modulated in 
the inflammatory compartment. 
I seek to define an integrated model of TNFRs and activated macro phages in the 
failing myocardium. I propose, as shown in Figure 3, a hypothesis that in cardiac 
macrophages, TNFR1 increases whereas TNFR2 opposes, or at least does not 
exacerbate, cellular activation as well as toxic metabolite and cytokine 
production. These changes serve to affect, in a dichotomous manner based on 
TNFRs, adjacent myocyte function and LV remodeling in response to ischemic 
injury. 
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MATERIALS AND METHODS 
Animals and Generation of Chimerjc Mice. Recipient C57BLl6 mice (8-12 
wks, 20-25 grams) were irradiated overnight (950 cGy) in an irradiation chamber 
to ablate the bone marrow compartment (Figure 4). The following day, femur 
bone marrow was harvested from donor green fluorescent protein (GFP) 
expressing transgenic (Tg) mice, WT C57BLl6 control, TNFR1-1-, or TNFR2-1-
(Jackson Labs) mice. 15 x 106 cells of donor bone marrow were injected via tail 
vein into recipient mice. Mice were quarantined for 30 days to ensure adequate 
resident cell turnover. Post-quarantine, flow cytometric analysis of donor CD45.2 
fluorescein isothiocyanate (FITC) vs recipient CD45.1 phycoerythrin (PE) was 
performed to determine percent chimerism. All study mice exhibited greater than 
90% chimerism. Briefly, for GFP Tg mice, a bacterial artificial chromosome 
(BAC) encoding the mouse Rag1 and Rag2 sequence was modified by the 
insertion of an enhanced green fluorescent protein gene into exon 1 of Rag2. 
TNFR 1-1- was achieved via insertion of a neomycin cassette at position 535 of the 
coding sequence on chromosome 6 [90]. For TNFR2-1- generation, homologous 
recombination techniques to target the Tnfr2 gene where used. Specifically, a 
construct containing a neomycin resistance gene under the control of the Pgk 
promoter was inserted into the second exon of the Tnfr2 gene resulting in loss of 
gene function [91]. 
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Figure 4. A: Bone marrow chimeric mice were generated by ablation of donor C57BU6 
mouse marrow via ovemight irradiation followed by reconstitution with either TNFR1-f-, 
TNFR2-/- or C57BU6 marrow. B: Chimerism was confirmed by flow cytometric analysis of 
donor CD45.2-FITC and recipient CD45.1-PE demonstrating greater then 90% chimerism. 
Coronary ligation and experimental protocol, All studies were performed in 
compliance with the NIH Guide for the Care and Use of Laboratory Animals 
(DHHS publication No. [NIH] 85-23, revised 1996). Permanent coronary ligation 
was performed as previously described [63,92] Anesthesia was induced in mice 
with tribromoethanol (0.25 mg/g IP). After induction, the mice were intubated and 
supported with a MiniVent Mouse Ventilator (Type 845, Harvard Apparatus) at 
125-150 breaths/minute depending on body weight (tidal volume 6.4 !JUg, PEEP 
5-7 cm H20). Anesthesia was maintained with 1% isoflurane. Heat lamps and 
heating pads were used to maintain body temperature at 3rC. Under sterile 
conditions, a left thoracotomy was performed in the 4th intercostal space, the 
heart exposed, and the pericardium opened. An 8.0 prolene ligature was passed 
and tied around the proximal left coronary artery, 1 mm distal to the left atrial 
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appendage border. Successful occlusion was confirmed by the production of 
pallor and dyskinesia in the distal myocardium. In sham animals, the suture was 
passed but not tied. The chest was then closed in layers using 5.0 silk, and the 
mice were allowed to recover. The total mice used for these studies were as 
follows: WTc n = 30; R1-/-c n = 30; R2-/-c n = 30. Mice were followed for 4 weeks 
following operation. 
Echocardiography. Under tribromoethanol (0.25 mg/g IP) sedation, 
echocardiography (M-mode, 2D, and Doppler) was performed at baseline and 4 
weeks post-operatively using a Philips Sonos 5500, 15 MHz linear array 
transducer, 120 Hz frame rate. Measured variables included the short-axis end-
diastolic (ED) and end-systolic (ES) diameter (D) and wall thickness (WT), and 
long-axis end-diastolic and end-systolic volume (EDV and ESV) using the 
modified Simpson's method. LV systolic function was indexed by either fractional 
shortening (FS = EDD-ESD/EDD) or single plane planimetered LV ejection 
fraction (EF = EDV-ESV /EDV). 
Histomorphometry and immunohistochemical analysis. Paraffin embedded 
tissue sections (5IJm) were de-paraffinized, rehydrated, and stained with Masson 
Trichrome (for collagen) using standard histologic techniques [63,92]. The 




Wheat Germ Agglutin (WGAl staining. Paraffin embedded tissue sections (5 
1lrTl) were de-paraffinized and rehydrated. They were then stained with WGA 
solution diluted to 5 Ilg/ml in PBS for 1 hour in a dark room at room temperature. 
The slides were washed and fixed with DAPI Antifade Reagent and sealed. Epi-
fluorescent microscopy (Nikon TE 200) was used for analysis. 
Real-time peR and mRNA guantitation. Total RNA was isolated from LV 
tissue using TRlzol reagent (Invitrogen), and cDNA was synthesized from 1 I-Ig 
RNA using the iScripFM cDNA Synthesis kit (BioRad). Relative levels of mRNA 
transcripts for atrial natriuretic factor (ANF), connective tissue growth factor 
(CTGF), TNF, interleukin (lL)-1~, IL-6, and IL-10were quantified by real-time PCR 
using Fast SYBR® Green (Applied Biosystems). GAPDH mRNA expression was 
used to normalize the data. Expression level of each targeted gene was 
normalized by subtracting the corresponding GAPDH threshold cycle (CT) values 













Table 1. Primers Used for Real-Time PCR 
Forward Primer Reverse Primer 
5'-CCTGTGTACAGTGCGGTGTC -3' 5'-AAGCTGTTGCAGCCTAGTCC -3' 
5'-AAGACACATTTGGCCCAGAC -$ 5'-TT ACGCCATGTCTCCGT ACA-$ 
5'-ACGGCATGGATCTCAAAGAC -3' 5' -TGGAAGACTCCTCCCAGGT A-3' 
5'-TCATTGTGGCTGTGGAGAAG ~' 5'-AGGCCACAGGTATTTTGTCG-3' 
5'-GTTCTCTGGGAAATCGTGGA -3' 5'-GGAAATTGGGGT AGGAAGGA -3' 
5'-TGCTATGCTGCCTGCTCTT A _3' 5'·TCATTTCCGAT AAGGCTTGG-$ 
5'-TGATGACATCAAGAAGGTGGTGAAG- 3' 5' -TCCTGGAGGCCATGTGGGCCAT-3' 
A NF, atrial natri...-etic factor; CTG F, oomective tissue growth factor; TNF, UTlor necrosis factor-a; 
IL, iltedetltin; GAPOH, glyceraldehydes phosphate dehydrogenase. 
Tissue harvest. Following the final echocardiographic or hemodynamic study, 
mice were given additional anesthesia with sodium pentobarbital (50 mg/kg IP), 
diastolic-arrested with LV. KCL, and the heart was rapidly excised and rinsed in 
ice-cold physiological saline. Ventricles and atria were dissected and weighed 
separately. Liver, kidneys, spleen, and lungs were dissected and weighed as 
well. Lungs were subsequently dried for 48 hrs at 60°C and weighed to yield 
wet-dry ratios. Tibia length was taken for tissue weight normalization. A short-
axis section of the LV was formalin fixed for 16 h, dehydrated in ethanol, and 
paraffin-embedded for subsequent histological studies. The remaining LV tissue 
was separated into infarcted (scar) and non-infarcted regions, snap-frozen in 
liquid nitrogen, and stored at -80°C for biochemical and molecular studies. Non-
infarcted tissue was used for molecular analyses. 
Flow Cvtometric Analysis of Peripheral Blood. Approximately 100 uL of 
peripheral blood was collected via facial vein technique [94] into BO Microtainer 
tubes with EOTA (BO Biosciences, 365973). Blood was then lysed with 2 mL 
RBC lysis buffer (eBiosciences, 00-4333-57) for 5 min on ice in a 15 mL conical 
centrifuge tube followed by PBS quenching via addition of 10 mL cold PBS. 
Cells were then centrifuged at 380g for 10 min/4°C and the supernatant was 
discarded. The pellet was resuspended in 400 uL of ice cold flow cytometry 
staining buffer (eBioscience, 00-4222-57) and divided into two plastic flow 
cytometry tubes yielding two 200 uL tubes for each animal. Each tube was 
subsequently incubated for 30 min on ice with fluorescently labeled cell surface 
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antibodies (0.6ug/106 cells) for the Monocyte Cell Panel: F4/80-Pacific Blue, 
CD11 b-PE. Cells were then centrifuged at 380g for 1 Omin/4 °C, and the pellet 
was resuspended in 400 uL of ice cold PBS. Samples were immediately 
analyzed on a BD LSRII flow cytometer equipped with 405, 488, and 633nm 
lasers and appropriate filter sets. A non-debris gate was established on a FSC 
vs SSC gate and positivity for respective surface markers was determined from 
subsequent histograms. Unstained and f1uorescently labeled respective Ig 
antibodies were analyzed to determine negative populations and set 
fluorescence threshold. Final analysis was performed using FlowJo software 
v.7.6. Activated monocytes were taken to be F4/80+CD11 b+. Blood was 
analyzed on all animals at baseline 1 day, 1 week, and 4 weeks post-infarction. 
Statistical analysis. Comparisons of experimental data were made using a 
repeated measures analysis of variance (ANOVA). Animal survival was 
evaluated by Kaplan-Meier analysis, and comparisons of survival between 
groups at specific time points was made by both Cox regression and long-rank 
statistics. Statistical significance was accepted at p < 0.05. 
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RESULTS 
Chimeric Mice Exhibit Similar Baseline Cardiac Phenotypes 
One of the initial concerns during the planning of this study was whether the 
generation of the chimeric model would in and of itself alter cardiac structure 
and/or function differentially between the three experimental groups. It therefore 
was necessary to determine if chimeric mice, had baseline differences in their 
cardiac phenotype. The concern was warranted due to the use of lethal doses of 
radiation during the process of generating the chimeric model and reconstitution 
of the bone marrow compartment with genetically modified cells. The baseline 
cardiac phenotype, in terms of myocardial volumes and cardiac performance 
determined by ejection fraction (EF) for the TNF R1-/- chimera mice thus far 
referred to as R1-/-c and the TNF R2-/- chimera group hence forth, R2-/-c, was 
not different from the control C56BU6 chimera, WTc. On the following page, 
representative long axis echocardiograms of the baseline studies are shown on 
the left and graphical demonstration of volumetric data, end diastolic volume 
(EDV), end systolic volume (ESV) and EF demonstrated on the right (Figure 5). 
The overall volumes are smaller universally then expected for naive mice. We 
believed that this was likely due to the radiation administered. The important 
fact, however, was that the animals demonstrated no difference amongst the 
groups at baseline. 
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Figure 5. A: Representative long-axis echocardiographs show no change in left 
ventricular size between WTc,TNFR1-1--c and TNFR2-/-c groups. Quantitative 
group data confirm this find ing. B. Graphical representation of group echo data 
showing no baseline changes in EDV, ESV, or EF. 
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Proof of Concept: Monocytes/ Macrophages are Activated in the Peripheral 
Blood in Chronic Heart Failure 
As the central theme of our hypothesis was that activated inflammatory cells play 
a detrimental and modifiable role in chronic HF, it was of paramount importance 
to prove monocytes were activated in a sustained manner in the peripheral blood 
in response to ischemic injury. In order to determine the level of monocyte 
activation in HF, WT mice where subjected to permanent coronary ligation. Flow 
cytometric analysis was performed to evaluate blood monocyte activation. 
Activated monocytes were identified as CD11 band F4/80 dual positive cells. A 
marked increase in this cell population was noted at 4 weeks post ligation (3.59 ± 
1.1 vs. 9.78 ± 0.4 % gate), indicating a sustained inflammatory reaction 
generated by myocardial injury. To insure that this same increase in 
mononuclear inflammatory cells also occurred in TNFR null animals, TNFR1-/-
and TNFR2-/- mice were subjected to the same protocol. Flow cytometric 
analysis of their peripheral blood for dual CD 11 band F4/80 positive cells yielded 
a similar finding with evidence of a pro-inflammatory milieu 4 weeks post injury in 
TNFR1-/- (4.17 ±. 0.76 vs. 7.74 ± 0.87 % gate) and TNFR2-/- (4.15 ± 0.96 vs. 






Figure 6. A: Representative flow cytometric analysis of actJvated blood monocytes at baseline 
on the left and at four weeks post ligation on the righL B: Graphical representation of each group 
at baseline and four weeks post Infarction 
Proof of Concept: Activated Macrophages Infiltrate the Failing Myocardium 
Producing Inflammatory Cytokines 
We next performed cardiac tissue analysis looking for infiltration of macrophages 
into chronically infarcted myocardium. Activated mononuclear cells in the 
periphery must infiltrate the infarcted myocardium in order to produce significant 
myocardial damage and dysfunction, given the typical juxtacrine effects of 
inflammatory cells. We first used green fluorescent protein (GFP) generated 
chimeric mice (GFPc), Le. somatic wild type and GFP positive bone marrow, to 
determine if inflammatory cell infiltration into the infarcted myocardium occurred. 
GFPc animals were subjected to permanent coronary ligation and followed for 
four weeks. They were then sacrificed and the myocardial tissue examined with 
fluorescent microscopy. Interestingly, we found GFP positive cells in and around 
the area of myocardial injury, since these animals were GFP chimeras, the 
fluorescent cells could only have been generated in the bone marrow and were 
therefore, inflammatory cells. We next sought to determine whether the infiltrating 
cells were in fact activated while in the myocardial tissue. To do this we used 
C57BL6 WT mice as well as TNFR1 and TNFR2 whole body knockouts. These 
animals were subjected to either sham operation or coronary ligation. Four 
weeks post ligation these animals were sacrificed and the myocardial tissue was 
immunostained with MOMA-2, a marker of macrophage activation, and anti-TNF 
antibody. Fluorescent microscopy was performed. MOMA-2 analysis revealed 
enhanced macrophage infiltration in the failing heart, especially in the border 
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zone myocardium. Importantly, MOMA-2 positivity was not significantly increased 
compared to sham in TNFR1 knockout HF hearts (NS) but exaggerated in 
TNFR2 knockout HF hearts compared to sham animals (p<O.05) (Figure 7). 
Moreover, dual immunofluorescent staining for MOMA-2 and TNF in failing 
hearts, revealed strong macrophage TNF expression, further indicative of cell 
activation. (Figure 7) These results confirmed infiltration of activated 
inflammatory cells into the failing heart, and suggested that these cells 
compromised a significant source of inflammatory cytokines. The functional 
significance of this was determined with further experimentation. 
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Figure 7. A: In GFP chimeric mice, GFP positive cells infiltrate the infarcted 
myocardium implying migration from bone marrow. B: Immunohistochemical 
identification of activated macrophages using anti-MOMA-2 in sham (top) and in 
failing mouse hearts (bottom). C: Quantification of MOMA-2 staining in WT, 
TNFR1-/- and R2-/- hearts. Activated macrophages were increased in WT and 
TNFR2-/- HF hearts (*p < 0.05 vs sham), but not in TNFR1-/- HF. Also, TNFR2-/-
HF had significantly more activated macrophages as compared to TNFR1-/- HF 
(p=0.012). D: On the left panel, WT HF sections were stained with either anti-
MOMA-2 for activated macrophages , anti-TNF (green, FITC-Iabeled secondary 
antibody), and DAPI to label nuclei (blue) , and imaged with confocal microscopy 
As seen in the overlay images, there was co-localization of TNF with macrophages. 
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Selective Loss of Either TNF Receptor in Inflammatory Cells Yields a Pro-
Survival Benefit 
There was no difference observed in the survival between the three chimeric 
0NTc, R1-/-c, and R2-/-c) sham groups (p=NS). However, when compared to 
WTc sham, WTc HF animals showed an approximately 40% mortality. This is in 
line with previously observed mortality rates for C57BLl6 permanent coronary 
ligation models in both our laboratory and others [63,92]. Interestingly, in post-
infarction HF, we found that ablation of either TNF receptor in the inflammatory 
cell compartment improved survival significantly over WTc HF animals (80% vs. 
60%). This can be seen in the Kaplan-Meier survival curve shown below (Figure 
8). This phenomenon of increased survival with ablation of either of the TNF 
receptors was also previously observed in somatic TNFR1 and R2 null mice [63]. 
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Figure 8: Kaplan-Meier survival curves from WTc, R1-/-c, and 
R2-/-c mice after coronary ligation (HF) or sham operation. 
Sham animals demonstrated significant improved survival over 
their HF counterparts. Interestingly, both R1-/-c and R2-/-c HF 
groups showed improved survival when compared to the WTc 
HF group. 
The Initial Level of Injury was Equivalent Between all HF Study Groups and 
not a Reason for the Difference in Survival Noted Between the TNF 
Receptor Knockout Chimeras and WT Chimeras 
To ensure no significant difference was present in the initial myocardial injury that 
might explain this difference in survival in the HF groups, infarct area as a 
percent of total LV area at 4 weeks was measured for each animal. This data 
demonstrated that there was no difference in the infarction area observed in the 
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3 groups (p=NS) indicating that the survival benefit observed was not from 
differences in initial injury. (Figure 9) 
Figure 9: Quantification of infarction area as percent of LV 
area demonstrating equivalent injury in each of the HF 
groups. 
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LV Remodeling and Dilatation post Infarction is Attenuated by the Selective 
Loss of TNFR1 in the Inflammatory Compartment, while Similar Loss of 
TNFR2 Demonstrates no such Benefit 
Four weeks following coronary ligation, LV tissue sections were obtained as 
described in the methods section. Demonstrated below are representative LV 
short axis tissue sections and M-mode echocardiograms corresponding to WTc 
sham and WTc HF, again demonstrating that permanent coronary ligation 
resulted in a substantial level of myocardial injury and LV dilatation. When 
comparing representative R1-/-c HF images, the magnitude of these changes 
was attenuated. An obvious decrease in LV dilatation is seen in the gross cross 
section and improved myocardial performance noted on M-mode. The R2-/-c HF 
example shows LV dilatation and systolic dysfunction similar to WTc HF. The 
R1-1-c and R2-/-c shams are phenotypically similar to the WTc sham, again 
demonstrating no significant differences in uninjured myocardium. (Figure 10) 
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Figure 10. A: Representative left ventricular short-ax-s cross sections. While hearts from all three HF groups were 
significantly increased in size over sham, gross changes between R2-/-c and WTc HF animals were Significantly greater 
when compared to R1-/-c HF. B: Representative M-mode echocardiograms. As with gross pathology, no apparent 
differences were observed between the WTc and R2-/-c HF groups, however significantly improved function was noted 
in the R1-/-c HF animals. R1-/-c and R2-/-c shams are not shown for simplicity but were not different from WTc shams. 
In vivo Measurements of Chamber Dilitation and Performance Demonstrate 
Improved LV Remodeling and Myocardial Performance with the Loss of 
TNFR1 in Inflammatory Cells 
The observation of exaggerated lV chamber dilatation in WTc HF and R2-/-c HF 
hearts compared with R1-1-c HF hearts were confirmed by group 
echocardiographic data. lV size was indexed by end diastolic and end systolic 
volume (EDV and ESV), and systolic function was indexed by lV EF. EDVand 
ESV were significantly increased in each of the HF groups when compared to 
respective sham animals. The degree of chamber dilatation, as measured by 
EDV, however, was attenuated in R1-/-c HF when compared with either WTc HF 
(96.7 ±. 13.7 vs. 65.7 ±. 13.8 IlL) or R2-/-c HF (111.1 ± 28.5 vs. 65.7 ±. 13.8 Ill). 
A similar effect was observed for ESV comparing WTc HF to R1-/-c HF (72.1 :!:. 
14.6 vs. 37.0 :!:. 9.7 )ll) and R1-1-c HF and R2-/-c HF groups (37.0 :!:. 9.7 vs. 85.6 
:!:. 22.9 IlL) (Figure 11). The R1-1-c HF group also demonstrated a much higher 
EF as compared to either WTc HF (42.9 .±. 4.2 vs. 25.5 :!:. 7.5 %) or R2-/-c HF 
animals (42.9 :!:. 4.2 vs. 22.3 .±. 4.6 %) (Figure 11). No significant difference was 
observed in either lV size or ejection fraction between R2-/-c and WTc HF 
(p=NS). (Figure 11) 
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Figure 11: Quantification of echocardiographic parameters of end diastolic volume (EDV). 
end systolic volume (ESV). and ejection fraction (EF). All HF groups had significantly 
increased volumes both EDV and ESV and reduced EF compared to sham indicative of 
LV dilatation and impaired systolic function . however the R1-/-c HF group demonstrated less 
change from the sham groups In all three parameters compared to the WTc and R2-/-c HF. 
R1-/-c and R2-/-c sham groups are not shown for simplicity but are not different from WTc sham 
Mice with Deletion of TNFR1 in Inflammatory Cells Demonstrated Less 
Pulmonary and Systemic Congestion and Myocardial Mass in HF 
Consistent with Improved HF Physiology 
Following animal sacrifice, analysis of tissue weights was performed as 
described in the methods section. An increase in LV mass and increased lung 
and liver weights consistent with LV hypertrophy and increased lung and liver 
water were seen in all HF groups compared to sham (p<O.05). In accordance 
with the echocardiography data showing less LV remodeling and improved 
performance in R 1-/-c failing hearts (Figure 11) there was a decrease in heart 
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size normalized to tibia length in R1-/-c HF when compared with either WTc HF 
(4.79 ±. 0.64 vs. 6.39 ±. 0.44 mg/mm) or R2-/-c HF (4.79 ± 0.64 vs. 6.85 ±. 1.05 
mg/mm) groups. When analyzing LV mass individually, again normalized to tibial 
length, a similar trend was noted upon comparing R1-/-c HF with either WTc HF 
(3.14 ± 0.20 vs. 3.91 ± 0.53 mg/mm) or R2-/-c HF groups (3.14 ± 0.20 vs. 4.07 ±. 
0.27 mg/mm). Additionally, R1-/-c HF had reduced lung and liver weights, 
compared with either WTc HF or R2-/~ HF (p<0.05). R2 HF and WTc HF 
demonstrated no significant differences in heart, LV, lung or liver weight (p=NS) 
(Figure 12). Pulmonary and systemic congestion, hallmarks of the 
pathophysiology of HF are indexed here by lung and liver weights mentioned 
previously. The R2-/-c and WTc HF groups had significantly higher lung and liver 
weights then the R1-/-c HF mice, demonstrating an attenuated HF physiology in 
the R1-/-c mice. 
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Myocyte Area and Atrial Natuiretic Factor (ANF) Expression were 
Significantly Attenuated in R1-/-c HF Mice Compared to Either R2-/-c or 
WTc HF Mice 
Myocyte area was assessed using wheat germ agglutin 0NGA) staining and 
representative images are shown in Figure 13. In each HF group there was an 
increase in myocyte size compared to sham, as is expected with a significant 
level of injury subsequently resulting in pathological hypertrophy. However, in 
the R1-1-c HF group this increase in size was attenuated when compared to 
either WTc HF (255.64 ± 64.98 vs. 325 ± 73.45 11m2) or R2-/-c HF (255.64 ± 
64.98 vs. 331.89 ± 71.87 11m2). This pattern was further supported by evaluation 
expression of ANF, a protein marker of myocyte hypertrophy. ANF expression 
was significantly increased in WTc HF hearts and R2-/-c HF hearts over sham 
(WTc HF 5.14 ± 1.34 fold increase; and R2-1-c HF 4.26 ± 2.04 fold increase), 
however, no significant increase was noted in the R1-/-c HF hearts compared to 
sham (1.19 ± 0.9 fold change) consistent with the decrease in myocyte 





Figure 13: Representative images of wheat germ agglutin staining (WGA). 
Shown are WTc, R1-/-c, and R2-/-c sham and HF. All HF groups demonstarted 
Myocyte hypertrophy compared to the sham groups. However, the R1 -/-c HF 
group had significantly less hypertrophy compared to either the WTc or 




Figure 14. A: Graphical quantification of myocyte area as measured by wheat germ agglutin syaining (WGA). 
All HF groups demonstrated significantly increased myocyte area when compared to their corresponding 
shams. However, the R1-J-c HF group had Significantly less hypertrophy compared to the other two HF groups. 
B: Quantified RT-PCR of atrial naturetic factor (ANF), confirming the hypertrophy data, the level of ANF in R1-J-c 
HF hearts was significantly less then either the WTc or R2-J-c HF groups. 
Decreased Total Fibrotic Area Seen in R1 HF Group Compared to Both R2 
HF and WTc HF groups 
Total LV fibrorotic area was assed using Trichrome staining. Shown in Figure 15 
are representative histomicrographs of non-infarcted, and remodeled 
myocardium, and the corresponding group quantitation of fibrotic area (Figure 
15). There was a significant increase in collagen deposition in all three HF 
groups when compared to their respective sham groups (p<0.05). However, this 
was most pronounced in the WTc and R2-/-c, and was less in R1-1-c HF 
compared to either WTc HF (5.48 ±. 2.26 vs. 16.10 ±. 8.16 % area) and R2-/-c HF 
(5.48 ±. 2.26 vs. 21.92 ±. 10.81 % area). (Figure 15) 
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Figure 15. A: Representative Trichrome staining of sham and HF hearts. Significant levels 
of fibrosis (blue) are seen In all HF groups compared to sham. B: Quantification of total myocardial 
fibrotic area demonstrates significant increased fibrosis in all HF groups compared to sham. however. 
R1-/-c HF had significantly less fibrosis following infarction then either WTc or R2-/-c HF groups. 
Attenuated Fibrosis was Observed in the R1-1-c HF Hearts in the Region 
Immediately Adjacent to the Infarction as well as Areas Remote to the 
Injury 
Trichrome analysis to delineate fibrotic burden of the border zone, the area 
immediately adjacent to the infarcted myocardium, and the remote zone, the area 
of LV uninvolved by infarction , demonstrated a similar pattern with regard to total 
fibrotic area. Specifically, in the border zone significantly increased fibrosis was 
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noted in all HF groups as compared with sham (p<0.05). However, there was 
significantly less borderzone fibrosis noted in R1-/-c HF compared to either 
R2-1-c HF orWTc HF (5.48 ±.2.26 vs. 16.10 ±.8.16 vs. 21.92 ± 10.81 % area, 
respectively). In the remote zone, no significant differences in fibrosis were 
noted between sham and R1-/-c HF (p=NS). The remaining HF groups, R2-/-c 
HF and WTc HF, both demonstrated increased fibrosis compared to sham. 
However, no significant differences were noted between R1-1-c HF and WTc HF 
(p=NS). There was however a significant increase in fibrosis in the remote zone 
in the R2-/-c HF group compared to either WTc HF (4.78 ±. 2.02 vs. 2.6 ±. 1.62 % 




Figure 16. A: Representative Trichrome staining of sham and HF hearts. Significant levels of fibrosis 
(blue) are seen in all HF groups compared to sham. B: Quantification of myocardia border zonel 
Fibrosis. All HF groups had significantly increased border zone fibrosis. R1-/-c HF animals had 
significantly less fibrosis than either WTc or R2-/-c HF. C: The Remote zone. demonstrated 
significantly Increased fibrosis in all HF groups compared to sham; however. R1-/-c HF had 
significantly less fibrosis following infarction than R2-/-c HF. 
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Myocardial Expression of Pro-Fibrotic Connective Tissue Growth Factor 
(CTGF) Parallels the Changes in LV Fibrosis Post Infarction 
RT-PCR was used to measure myocardial expression of connective tissue 
growth factor (CTGF) a pro-fibrotic protein. The pattern of post infarction LV 
fibrosis demonstrated in WTc, R1-/-c, and R2-/-c HF groups discussed previously 
was supported by analysis of CTGF gene expression, which exhibited reponses 
analogous to the change in tissue fibrosis. Specifically, all HF groups 
demonstrated significantly increased cardiac expression of CTGF compared to 
sham (p<0.05). Interestingly, R1-/-c HF hearts showed a significant fold 
decrease in CTGF expression compared to either WTc HF (1.66 ± 0.50 vs. 2.28 
.:!:. 0.62 fold increase) and R2-/-c HF hearts (1.66 ±. 0.50 vs. 2.61 .:!:. 1.22 fold 
increase) (Figure 17). 
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Figure 17. A: Representative Trichrome staining of sham and Hf hearts 
in the WTc, R1 -I-c, and R2-/-c groups. B: Quantified RTPCR values of myocardial 
expression of connective tissue growth factor (CTGF). CTGF was increased 
in all HF groups over their respective shams. Compared to R2-/-c HF and WTc 
HF, R1-I-c HF had significantly lower levels of CTGF expression. 
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No Significant Difference was noted in Activated Peripheral Monocytes 
(F4/80+/ CD11b+) Amongst the Three Study Groups in NaIve Animals 
Flow cytometric analysis was performed on peripheral blood samples obtain from 
naive mice in each of the three study groups, WTc, R1-/-c, and R2-/-c. Activated 
monocytes were identified as dual positive F4/80 and CD11 b cells. No 
significant difference was noted between any of the three groups at baseline 
(p=NS). (Figure 18) 
Figure 18: Activated momocytes as defined by dual positivity of 
F4/80 and CD11b by flow cytometry in the peripheral blood of 
Na"lve WTc, R1 -/-c, and R2-/-c mice. No significant difference 
was noted between any of the groups. 
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An Exaggerated Level of Activated Monocytes (F4/80+1 CD11b+) was 
Demonstrated by Flow Cytometry in the Peripheral Blood of R2-1-c HF Mice 
in Response to Myocardial Injury 
Activated monocytes, identified as cells dual positive for F4/80 and CD11 b by 
flow cytometric analysis, were significantly increase in all HF groups compared to 
their respective baselines and shams at all time points observed, with the 
exception of R1-/-c HF at 1 week post infarction. Interestingly the R2-/-c HF 
group demonstrated significantly higher levels of circulating activated monocytes 
compared to WTc HF at 1 day (15.32 ±. 4.41 vs. 12.10 ±. 1.24 % gate) and 4 
weeks (12.06 ±. 1.73 vs. 5.90 ±. 0.75 % gate) post infarction, and at all observed 
timepoints compared to R1-/-c HF 1 day (15.32 ±.4.41 vs. 8.19 ±3.08 % gate), 1 
week (10.40 ±. 1.67 vs. 5.81 ±2.27 % gate), and 4 weeks (12.06 ± 1.73 vs. 6.68 
± 0.94 % gate). This supports an important role for TNFR1 in the activation of 
monocytes in HF (Figure 19). 
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Figure 19: Quantified values of activated monocytes, identified as dual positive cells 
(F4/80 and CD11 b) by flow cytometry, in the peripheral blood of WTc sham, WTc 
HF, R1-I-c HF, and R2-/-c HF. R1-/-c and R2-/-c shams not shown, but were not different 
from WTc sham. R2-/-c HF demonstrated an exaggerated increase in activated 
monocytes compared to the WTc and R1-/-c HF groups at all time points post infarction 
with the exception of WTc HF at 1 week post infarction. 
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Loss of Inflammatory Cell TNFR1 Attenuates Myocardial Inflammation in 
the Failing Heart 
RT-PCR was used to measure cardiac expression of the pro-inflammatory TNFa, 
IL-1~, and IL-6, as well as the anti-inflammatory cytokine IL-10. TNFa expression 
was significantly increased in WTc HF over sham (1.64 ± 0.33 fold increase). 
Interestingly, there was no TNFa upregulation, as compared to sham, in either 
R1-1~ HF (0.42 ± 1.95 fold change) or R2-/-c HF (1.02 ± 0.75 fold change) 
(Figure 20). These findings indicated that both TNFRs need to be functional in 
the inflammatory compartment to induce TNF expression in the failing 
myocardium. R1-/-c HF also showed non-significant fold changes in the levels of 
IL-1~ (0.53 ± 1.88 fold change) and IL-6 (1.50 ± 1.2 fold change) compared to 
the R1-/-c sham. The absolute fold change in IL-1~ in the R1-/-c HF group was 
significantly lower than in the R2-/-c HF (0.53 ± 1.88 vs. 1.72 ± 1.31 fold change) 
and WTc HF (0.53 ± 1.88 vs. 1.86 ± 0.55 fold change) groups. This indicates 
less myocardial inflammation in the R1-1-c HF hearts as compared to both WTc 
and R2-/-c HF, indicating that TNFR1 signaling in inflammatory cells is required 
for myocardial cytokine expression. The R2-/-c HF group demonstrated a 
predictable and significant increase in both IL-1~ (1.72 ± 1.31 fold increase) and 
IL-6 (2.13 ± 1.24 fold increase) gene expression relative to sham. The WTc HF 
hearts exhibited similar IL-1~ and IL-6 expression as compared with R2-/-c HF 
hearts. Myocardial expression of IL-10, a well-established anti-inflammatory 
cytokine, was increased in the R1-/-c HF group compared to sham (1.57 ± 0.80 
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fold increase), but not in WTc or R2-/-c HF, consistent with the observed blunted 




Figure 20. A: RTPCR quantified myoycardial expression of tumor necrosis factor alpha (TN F), B: interleukin (IL) 
6 (IL-6), C: IL-10, and 0: IL-1B. 
Conclusions 
The data in this chapter demonstrated that selective loss of TNFR1 in 
inflammatory cells profoundly influences post-infarction cardiac remodeling and 
protects the failing myocardium from many of the deleterious processes that 
define the pathology of HF. Specifically, deletion of TNFR1 in the inflammatory 
compartment alleviated contractile dysfunction and chamber dilatation, LV and 
myocyte hypertrophy, interstitial fibrosis, peripheral monocyte activation, and 
myocardial inflammation with significant reductions in TNF, IL-6, and IL-1~ 
expression and increases in IL-10 expression. 
Conversely, selective loss of TNFR2 in inflammatory cells did not significantly 
influence post-infarction cardiac remodeling in that the LV performance and 
dimensions measured by echocardiography were not significantly different from 
the WTc HF group. It did, however, modestly augment interstitial fibrosis, 
compared to WTc, and reduce TNF expression. 
Nonetheless loss of either TNFR1 or TNFR2 in inflammatory cells improved 
survival over WTc HF mice. This is an interesting finding in that, even though 
loss of TNFR2 did not significantly change the phenotypic picture of chronic HF 
with regards to LV function, inflammatory cytokine production (with the exception 
of TNFa), and myocyte hypertrophy, it offered a survival benefit. This is even 
more interesting in that it correlated with previously reported data [63] indicating 
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a similar survival benefit in TNFR -/- HF mice despite seemingly unimproved 
myocardial dysfunction post coronary ligation. Possible explanations for this 
include scar stabilization, decreased electrical abnormalities, and decreased 
systemic effects of HF, all likely the result of more complex intercellular and 
intracellular TNF related signaling mechanisms then are currently appreciated. 
Myocardial rupture is a prominent cause of death early in the time course of post 
infarction remodeling in mice. While a slight increase in myocardial fibrosis was 
noted in the R2-/-c HF hearts, we can not fully determine the level of scar 
stability, i.e. its resistance to mechanical forces. Improved tensile strength 
would certainly better resist myocardial rupture. Sudden cardiac death (SeD), a 
product of malignant ventricular arrhythmias, is common in the sub acute 
infarction period. While this is difficult to monitor in an animal model it is likely 
this represents, as it does in humans, a significant cause of mortality. 
Differences in scar formation and fibrosis are well known to influence these 
electrical abnormalities. While differences in remodeling were evident in the R1-
/-c HF mice, it was less so with the R2-/-c HF animals. More sophisticated 
analysis of the fibrotic areas and electrical behavior of these animals would be 
needed to determine the likelihood of this explanation. Likewise, worsening 
systemic HF physiology can contribute to mortality. The observed requirement of 
both TNF receptors to induce myocardial TNFa production could playa role in 
improved HF physiology from the R2-/-c group, although from the analysis of liver 
and lung weights, along with echocardiographic data, it appears this is unlikely to 
be the case. 
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It is apparent from this work that modulation of global inflammatory cell function 
induces significant localized changes in cardiac remodeling, and that TNF 
receptor signaling plays an important role in these effects. Inflammatory cell-
localized TNFR1 exacerbates post-infarction LV remodeling and is required for 
the genesis of a pro-inflammatory state in failing myocardium. Inflammatory cell-
localized TNFR2 imparts modest beneficial anti-fibrotic effects in the remodeling 
heart. Independent of the myocyte-specific effects of TNF, TNF-dependent 
inflammatory cell responses are critical for the progression of post-infarction 
remodeling in HF. 
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CHAPTER V 
AIM #2: TUMOR NECROSIS FACTOR SIGNALING IN MACROPHAGES 
MODULATES JUXTACRINE MACROPHAGE-MYOCYTE INTERACTIONS IN 
HEART FAILURE 
BRIEF PREVIEW 
Background: While our previous findings indicated that selective ablation of 
bone marrow TNF Receptor 1 is beneficial, and that ablation of TNF Receptor 2 
yields modest detrimental effects in HF, the exact underlying cellular 
mechanisms of these effects are still unknown. In this aim, we will discuss 
potential mechanisms whereby infiltrating macrophages can interact with 
myocytes. To date it is unknown whether induction of myocardial dysfunction is a 
paracrine, cytokine mediated event or if actual cell-ta-cell interaction is 
necessary; therefore, we will determine both paracrine and juxtacrine interactions 
between the macrophage and cardiomyocyte. 
Methods: Heart failure was induced by permanent coronary artery ligation in 
C57BLl6, TNFR1-1-, and TNFR2-/- mice (Jackson Labs) as described previously. 
The HF mice were then treated with an intraperitoneal injection of the 
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macrophage attractant thioglycollate. Five days later, peritoneal macrophages 
were collected via peritoneal lavage and placed in co-culture with freshly isolated 
na"ive cardiomyocytes. Macrophages isolated from sham operated animals 
served as the negative control, whereas, macrophages isolated from sham 
animals and artificially stimulated with lipopolysaccharide (LPS) served as the 
positive control. Cardiomyocyte contractile function was measured via video-
edge detection (lonOptix) during digital field stimulation (1 Hz) under various 
conditions: 1) baseline cardiomyocyte contraction, 2) contraction following 
addition, but no attachment, of isolated macrophages, and 3) contraction 
following addition and attachment of macrophage and cardiomyocyte for 15 
minutes. In separate experiments, cardiomyocytes were pre-loaded with the 
general marker of oxidant stress 5-(and-6)-carboxy-2', 7' -dichlorofluorescein 
diacetate (DCFDA), a fluorescent indicator of ROS levels, and subjected to the 
same experimental conditions. 
RESULTS: Upon physical attachment of wild type LPS-stimulated macrophages, 
cardiomyocytes exhibited significantly depressed sarcomeric shortening (4.8 ± 
1.9 vs. 10.5 ± 2.1 % shortening). This was determined to be a solely juxtacrine 
effect since addition of stimulated macrophages, without cardiomyocyte 
attachment, had no significant impact on sarcomeric shortening (9.26 ± 3.54 vs. 
10.5 ± 2.1 % shortening). This effect was mirrored in macrophages isolated from 
HF animals without pre-stimulation with LPS (4.5 ± 2.8 vs. 10.5 ± 2.1 % 
shortening), implying that macrophages are sufficiently pathologically activated in 
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HF for the induction of myocyte dysfunction. Interestingly, while attachment of 
-,/-
macrophages isolated from TNFR1 HF animals still induced cardiomyocyte 
contractile depression as compared to wild type controls, the resultant 
depression was significantly altered as compared with WT HF macrophages 
(7.06 ± 1.44 vs. 4.5 ± 2.8 % shortening). Conversely, TNFR2-1- HF macrophage 
augmented myocyte contractile dysfunction upon cell-to-cell interaction (2.80 ±. 
0.19 vs. 4.5 ±. 2.8 % shortening). Cell contact between macro phages and 
cardiomyocytes pre-loaded with the oxidant stress indicator DCF-DA, revealed 
30 fold increased myocyte oxidant stress 15 minutes following attachment of WT 
HF macrophages, and abrogation of this response upon attachment of TNFR1-'/-
HF macrophages. Conversley, TNFR2-'/- HF macrophage attachment 
significantly increased myocyte oxidant stress as compared to WT HF 
macrophages. 
CONCLUSIONS: We have provided mechanistic insight into the potential role of 
tissue macrophages in the production of contractile dysfunction and the first 
known report that the TNF receptors have divergent roles not only in in vitro 
single cell line culture models, but in cell-to-cell macrophage/cardiomyocyte 
interaction and function. In the infarcted animal, peripheral blood macrophages 
were pathologically activated and infiltrated the myocardium. Our previous data 
imply that many of the effects of these infiltrating cells may be most pronounced 
in the infarct border zone (Le., changes in extracellular matrix components) and 
may, at least in part, be dependent on the interplay of various inflammatory 
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mediators (iNOS, TNF, etc.). The effects of direct interaction between infiltrating 
macrophages and cardiomyocytes, and the role of TNFR-specific responses, are 
unknown. Data from this Aim indicates that direct, juxtacrine interactions between 
activated infiltrating macrophages are sufficient to induce oxidant stress and 
contractile depression in cardiomyocytes. This process is further influenced by 
the differential roles of immune cell TNF receptors. Moreover, our data confirm 
previous studies, in that paracrine (as opposed to juxtacrine) interactions 
between macrophages and cardiomyocytes were not sufficient to cause 
contractile dysfunction in the in vitro, co-culture setting. 
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INTRODUCTION 
While recent evidence has provided some mechanistic insight into the role of 
inflammation in the heart failure, much has been left undetermined. The role of 
the "foundation cytokine" TNF in HF remains unclear. Specifically, while much is 
known regarding the divergent pathways of generalized TNF receptor 1 and 2 
signaling, the possibly critical contribution of cellular source has not been 
determined until this study. Aim 1 of this project provides the first evidence that 
the source of TNF receptor is critical for beneficial or detrimental function (Le. 
whereas inflammatory cell-specific TNFR1 ablation is beneficial to pathologic 
remodeling, TNFR2 ablation is modestly detrimental); however, this only further 
warrants studies into the cellular interactions between infiltrating inflammatory 
cells and the injured myocardium, specifically the cardiomyocyte itself. 
Therefore, we extended our studies in Aim 2 to more clearly delineate the 
underlying mechanisms through which these beneficial or detrimental processes 
may occur. 
While Aim 1 provides insights into the in vivo roles of the inflammatory cell TNF 
signaling in heart failure [63, 95], it remains unknown whether these effects are 
secondary to changes in the microenvironment, changes in the surrounding and 
supporting cells in the ischemic areas, or alterations in direct interactions 
between cardiomyocytes and infiltrating cells. Furthermore, if interactions 
between myocytes and inflammatory cells are a critical component (as we 
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hypothesize), is this effect controlled by the macrophage or other infiltrating bone 
marrow cells? In this Aim we will attempt to uncover answers to these and other 
questions. 
In addition to cellular source, the downstream effects on cardiomyocyte function 
are of critical importance as well. Are the observed effects secondary to changes 
within the cardiomyocyte or localized solely to the extracellular matrix and 
environment? If localized to the cardiomyocyte one suspect process involves 
myocardial oxidative stress. Myocardial generation of oxidative stress is a well 
known effect of the heart failure state [96] and is a known cause of a myriad of 
pathologic changes in failing myocardium including contractile dysfunction via 
disruption of contractile proteins [97]. However, the exact mechanism of this 
oxidant increase and the subsequent changes induced remain elusive. While we 
and others have suggested that infiltrating inflammatory cells in myocardium may 
contribute to oxidant stress-induced cardiac dysfunction, to-date only one paper 
hints at the possible role of the physical interaction of these cell types in the 
generation of oxidative stress [89]. In this elegant study, it was shown in an in 
vitro, cell co-culture model of neutrophil-cardiomyocyte interaction that 
neutrophils from septic animals were sufficiently activated to induce oxidant 
stress and ensuing contractile dysfunction in cardiomyocytes. 
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This important work is consistent with our findings of improved cardiac 
-/-
remodeling and oxidant stress in the in vivo HF model with TNFR1 chimerism. 
While exciting, it remains unknown whether inflammatory cells, activated in vitro, 
function in the same manner as chronically activated inflammatory cells in HF. 
Secondly, it is unknown whether macrophages in HF are sufficiently activated to 
induce oxidant stress effects in cardiomyocytes in a manner analogous to sepsis-
activated neutrophils. While these questions remain unanswered to date, it is 
notable that macrophages, like neutrophils, produce the foundation cytokine TNF 
in response various stimulants [98,99]. Taken together with our data that 
macrophages infiltrate the myocardium and are activated during heart failure, we 
hypothesize that macrophage-cardiomyocyte interaction in the failing heart is 
sufficient to induce contractile dysfunction via mechanisms related to free radical 




MATERIALS AND METHODS 
Animals. For these studies, commercially available C57BLl6 (WT), TNFRf/-, 
and TNFR2-1- mice (Jackson Labs) were used. The mice were maintained in the 
University of Louisville Research Resources Center. All studies were performed 
in compliance with the NIH Guide for the Care and Use of Laboratory Animals 
(DHHS publication No. [NIH] 86-23, Revised 1996). 
Coronary ligation and experimental protocol. Permanent coronary ligation 
was performed as previously described [63,92]. Anesthesia was induced in mice 
with tribromoethanol (0.25 mg/g IP). After induction, the mice were intubated and 
supported with a MiniVent Mouse Ventilator (Type 845, Harvard Apparatus) at 
125-150 breaths/minute depending on body weight (tidal volume 6.4 !JLlg, PEEP 
5-7 cm H20). Anesthesia was maintained with 1 % isoflurane. Heat lamps and 
heating pads were used to maintain body temperature at 3rC. Under sterile 
conditions, a left thoracotomy was performed in the 4th intercostal space, the 
heart was exposed, and the pericardium was opened. An 8.0 prolene ligature 
was passed and tied around the proximal left coronary artery, 1 mm distal to the 
left atrial appendage border. Successful occlusion was confirmed by the 
production of pallor and dyskinesia in the distal myocardium. In sham animals, 
the suture was passed but not tied. The chest was then closed in layers using 5.0 
silk, and the mice were allowed to recover and followed for 4 weeks. The total 
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TNFR2 (n = 10). Mice were followed for 4 weeks following operation, and were 
used for macrophage harvest. 
Isolation of mouse cardiomyocytes. Na'ive mice were deeply anesthetized with 
pentobarbital (80 mg/kg 1M) and given heparin 10 U/g Lp. The heart was rapidly 
2+ 
excised, and Ca tolerant mouse ventricular myocytes were isolated by modified 
Langendorff perfusion and collagenase digestion as previously described [1,3]. 
Briefly, the aorta was cannulated with retrograde perfusion of Tyrode buffer (in 




-18, Glucose-11, HEPES-4, BOM-10, 
Taurine-30, Glutathione-10) followed by 12 min collagenase perfusion. Atria were 
removed, and ventricular tissue was minced in collagenase mince buffer (tyrode 
buffer supplemented with 0.001 % collagenase and 0_003% albumin), passed 
through a 120 um mesh (Whatman) into a 1S mL conical tube, and allowed to 
settle for 10 min. Supernatant was discarded, and the remaining cells were 
2+ 
mixed with 2SuM Ca supplemented Tyrode buffer. This process was repeated 
2+ 
with SO,1 00,2S0, and SOOuM Ca supplemented buffer. Finally, cells were plated 
4 2 
at a density of 10 rod-shaped cells/cm in serum-free supplemented OM EM 
medium (with albumin 0.2%, L-carnitine 2mM, creatine SmM, taurine SmM, L-
glutamine 1.3 mM, insulin 0.1 mM, triiodothyronine 0.1 nM, pyruvate 25 mM, 
BOM 10 mM, and penicillin/streptomycin 0.1% (cardiomyocyte media, CMM)) at 
37°C in S% CO
2 
until experimentation_ Cell viability was typically 75-80%, as 
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assessed by trypan blue exclusion. Preparations with less than 75% viability 
were discarded. 
Isolation of peritoneal macrophages. C57BU6, TNFR1-1-, and TNFR2-1- sham 
or HF mice were injected ip with 3 mL Brewer thioglycollate (TG) medium 
(Sigma, B2551) 5-7 days prior to harvest. Mice were euthanized with CO , 
2 
followed by cervical dislocation, and cells were collected in a 50 mL conical tube 
on ice via peritoneal lavage with cardiomyocyte media. Macrophages were then 
isolated from lavage fluid by density gradient purification followed by washing 
and resuspension in cardiac myocyte media (CMM) to a final concentration of 
6 
2.5x10 celis/mL. The macrophage phenotype was confirmed with FITC-Iabeled 
F4/80 cell surface staining in a small aliquot. Approximately 99% of purified cells 
were determined to be positive. 
Co-culture experimental protocol. Isolated ventricular cardiomyocyte function 
with and without macrophage attachment was determined using an lonOptix 
myocyte contractility system (Milton, MA). C57BU6 cardiomyocytes were utilized 
-1-
for all studies, and macrophages from C57BU6, TNFR1 ,and TNFRZI- sham or 
HF mice (Jackson Labs, Bar Harbor, ME) were utilized where noted (Figure 21). 
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Approximately 4 hours after isolation, 10 cardiomyocytes (10 celis/mL) were 
placed into the contraction system and perfused with HEPES buffer (in mM: 
NaCI-137, KCI-4.9, MgSO ·7H 0-1.2, Glucose-15, HEPES-20, NaH PO -1.2, 




-1.8). Baseline sarcomeric shortening was determined during 1 Hz field 
6 
stimulation for 5 minutes. Macrophages (100 uL of 2.5x10 cells/mL) were then 
introduced into the system and allowed to attach for 15 minutes. For HF 
macrophage studies, cells were harvested from animals 4 weeks post-infarction, 
and for LPS studies, harvested cells were treated with 5 ug/mL LPS (Sigma) for 4 
hours prior to use. Post-attachment, sarcomeric shortening was again 
determined via 1 Hz stimulation for 5 minutes. For in vitro reactive oxygen 
species production experiments, cardiomyocytes were preloaded with 2 uM 6-
carboxy-2',T-dichlorodihydrofluorescein diacetate acetoxymethyl ester 
(Molecular Probes) followed by washing to ensure no residual DCFDA in media. 
Preloaded myocytes were then loaded into chambered borosilicate coverglass 
systems and non-OCFDA loaded macrophages were introduced. Immediately 
upon macrophage-myocyte interaction, baseline epifluorescent pictures were 
started and continued every 2 minutes for 15 minutes. After 15 minutes, 
brightfield images were obtained in order to quantitate number of macrophages 
attached. All fluorescent studies were preformed on a Nikon Eclipse TE2000-U 




Figure 21. For myocyte contraction studies (left) WT cardiomyocytes were co-cultured with WT LPS 
stimulated, WT HF-derived, TNFR1 -1- HF-derived, and TNFR2-1- HF-derived and LPS stimulated 
peritoneal macrophages. For free radical production studies, WT myocytes were co-cultured with WT 
sham, WT HF, TNFR1 -1- HF, and TNFR2-1- HF peritoneal macrophages. 
Flow Cytometric Analysis of Peripheral Blood. Approximately 100 uL of 
peripheral blood was collected via facial vein technique [94] into BO Microtainer 
tubes with EOTA (BO Biosciences, 365973). Blood was then lysed with 2 mL 
RBC lysis buffer (eBiosciences, 00-4333-57) for 5 min on ice in a 15 mL conical 
centrifuge tube followed by PBS quenching via addition of 10 mL cold PBS. 
Cells were then centrifuged at 380g for 10 min/4°C and supernatant was 
discarded. The pellet was resuspended in 400 uL of ice cold flow cytometry 
staining buffer (eBioscience, 00-4222-57) and divided into two plastic flow 
cytometry tubes yielding two 200 uL tubes for each animal. Each tube was 
subsequently incubated for 30 min on ice with fluorescently labeled cell surface 
antibodies (0.6ug/106 cells) for the Monocyte Cell Panel: F4/80-Pacific Blue, 
C011 b-PE. Cells were then centrifuged at 380g for 1 Omin/4 °C, and the pellet 
was resuspended in 400 uL of ice cold PBS. Samples were immediately 
analyzed on a BO LSRII flow cytometer equipped with 405, 488, and 633nm 
lasers and appropriate filter sets. A non-debris gate was established on a FSC 
vs SSC gate and positivity for respective surface markers was determined from 
subsequent histograms. Unstained and fluorescently labeled respective Ig 
antibodies were analyzed to determine negative populations. Final analysis was 
performed using FlowJo v.7.6. Activated mononcytes were taken as 
F4/80+C011b+. 
Statistical analysis. Comparisons of experimental data were made using a 
repeated measures analysis of variance (ANOVA). Animal survival was 
evaluated by Kaplan-Meier analysis, and comparisons of survival between 
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groups at specific time points was made by both Cox regression and long-rank 
statistics. Statistical significance was accepted at p < 0.05. 
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RESULTS 
Proof of Concept: Thioglycol/ate Elicited Peritoneal Macrophages are 
Positive for the Macrophage Marker F4/80 and Functional and Collagenase 
Disassociated Cardiomyocytes are Viable 
Seven days post peritoneal injection of thioglycollate, cells harvested via 
peritoneal lavage exhibited the morphology (lobed nucleus) and size (1 0-12um in 
diameter) characteristics of macrophages (Figure 22A) upon light microscopy. 
6 
Approximately 10-15 x 10 cells were harvested from each mouse and diluted 
into cardiomyocyte media. To confirm macrophage identity, immunofluorescent 
staining was performed for the classical macrophage marker F4/80 (FITC-
labeled). Nearly all cells were positive (99%) for the surface marker F4/80. 
(Figure 228) While confirmation of macrophage phenotype was important, it was 
equally critical to assess the ability of these cells to become activated upon 
stimulation. To this end, we developed a protocol for macrophage stimulation 
outlined in Figure 23A. One day post LPS stimulation, macrophages produced 
significantly greater amounts (2.5-fold) of NOx than unstimulated macrophages. 
Interestingly, these cells continued their stimulated state even 4 hours after 
withdrawal of the LPS stimulus. (Figure 238) We also isolated mouse 
cardiomyocytes via modified Langendorff perfusion with collagenase digestion. 
The isolated cells were calcium-tolerant and of normal morphological size and 
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shape (rod shape, approximately 100-120um) and behaved normally under field 
stimulation. (Figure 23C) 
SrightfieJd F4I80FITC Overlay 
Figure 22. A: 5-7 days post peritoneal thioglycollate injection, peritoneal 
macrophages were harvested via lavage (left image). Macrophage phenotype 
was confirmed through FITC labelled F4/80 surface staining (right image). B: 
Confocal microscopy confirms expected macrophage phenotype (brightfield 
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Figure 23: A: Isolated macrophage function was determined via the outlined 
protocol. B: One day post LPS stimulation, macrophages are active and 
produced 2.5-fold higher amounts of NOx. This activation continued after 
withdrawal of the initial stimulus. C: Freshly isolated cardiomyocytes exhibited 
normal morphological features. 
LPS-Stimulated Macrophages Induce Contractile Dysfunction Upon 
Attachment to Cardiomyocytes 
Upon introduction of LPS-stimulated peritoneal macrophages into the 
cardiomyocyte co-culture chamber, macrophages settled and attached to the 
surface of surrounding cardiomyocytes (Movie 1, Figure 24). When stimulated at 
1 Hz, the normal myocyte sarcomeric shortening was depressed approximately 
50% from baseline (4.8 ± 1.9 vs 10.5 ± 2.1 % shortening) and the duration of 
contraction increased. (Figure 24 Lower) 
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Figure 24. Upper: Movie of normal cardiomyocyte contraction at 1 Hz in na·ive 
and macrophage-attached cell. Lower: Representative contraction trace 
depicting both contractile depression and lengthening of the time of contraction 
upon macrophage attachment. 
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LPS-Stimu/ated Macrophages cause Myocyte Dysfunction in a Juxtacrine 
but not Paracrine Manner 
While it was an important finding that macrophage attachment to myocytes 
induced contractile dysfunction, it was equally important to determine whether 
these cells can exert detrimental effects in a paracrine fashion in the absence of 
attachment. This is especially important in the setting of the failing heart, where 
infiltrating cells mayor may not be in direct contact with a given cardiomyocyte. 
In fact, in Aim 1 we have shown that while macrophages infiltrate the failing heart 
and are active, they do so in small but sufficient numbers. Therefore, one could 
conclude that macropahges are able to either: 1) exert influences in small 
numbers via paracrine effects in the local microenvironment or 2) exert effects in 
the local environment via process extension and direct contact with 
cardiomyocytes. Sarcomeric shortening in cardiomyocytes both in close 
approximation to, but not in contact with, and in direct physical contact with LPS-
activated macro phages was measured via co-culture field stimulation and lon-
Optix imaging software. Group data revealed that while cardiomyocyte 
sarcomeric shortening was significantly depressed from baseline levels upon 
direct physical contact with LPS stimulated macrophages (10.19 ±. 2.74 vs. 4.96 
.±. 1.97 % shortening) there was no significant difference in the unattached group 
(10.19 .±. 2.74 vs. 9.26 .±. 3.54 % shortening) despite cell-cell proximity between 
macrophages and cardiomyocytes in this group. (Figure 25) This finding 
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represents one of the first reports detailing the significant role of physical cell-to-









Figure 25. Representative images and group data for myocyte sarcomeric 
shortening at baseline (left), upon close proximity of macrophages but no 
attachment (paracrine response, center), and upon macrophage attachment 
Uuxtacrine response, right). 
Importantly, no significant change in cardiomyocyte function was noted from 
baseline levels when non-stimulated, na"lve macrophages were physically 
attached to myocytes (data not shown). This important distinction clearly 
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implicates the role of the activated macrophage in the pathogenesis of myocyte 
dysfunction and correlates closely with our previous data implicating the 
activated, infiltrating peripheral blood macrophages in the pathogenesis of 
cardiac dysfunction in HF. 
Heart Failure-Derived Macrophages are Sufficiently Activated to Induce 
Cardiomyocyte Contractile Depression 
Having shown that LPS-stimulated macrophages induce contractile dysfunction, 
we next examined whether tissue macrophages in heart failure are sufficiently 
activated to mirror this response. As shown in Figure 26A, in the absence of cell 
attachment, wild-type heart failure-derived macrophages did not depress 
myocyte contraction over baseline (11.6 ± 1.3 vs. 9.6 ± 3.1 % shortening), again 
suggesting the lack of a paracrine effect. However, direct physical contact of 
wild-type, heart failure-derived macrophages induced severe contractile 
depression analogous to the effects of LPS-stimulated macrophages (4.5 ± 2.8 
vs. 9.6 ± 3.1% shortening). Figure 26B shows a representative image of 








Figure 26. A: Group myocyte contraction data reveal a significant depression in sarcomeric 
shortening in the attached , WT HF-derived macrophage treated group (orange bar) (p=O.001 vs WT 
HF unattached). B: Representative example of macrophage (white arrows) attachment to 
cardiomyocyte. 
HF-Derived Macrophage-Myocyte Physical Interaction Induces Contractile 
Dysfunction in a TNFR-Divergent Manner 
As our in vivo studies (Aim 1) implicated changes in inflammatory cell-localized 
TNF receptors 1 and 2 in the pathogenesis of LV remodeling from the molecular 
level to gross function, we next sought to investigate TNFR specificity in the in 
vitro cell co-culture model. WT, TNFR1-1- and TNFR2-1- mice were subjected to 
coronary ligation or sham operation. After 4 weeks peritoneal macrophages 
were isolated via thioglycollate elucidation. Isolated Rr/- and R2-1-
macrophages were co-cultured with wild-type cardiomyocytes thereby yielding in 
vitro replicas of our in vivo mouse models. As seen in Figure 27 and in 
corroboration with our in vivo experiments, ablation of macrophage specific 
TNFR1 significantly alleviated macrophage-induced myocyte dysfunction. While 
still significantly depressed from baseline levels, cardiomyocte function was 
improved from WT HF macrophage attachment levels (7.06 :!:. 1.44 vs. 5.00 :!:. 
1.54% shortening). Conversely and still in support of our in vivo data from Aim 1, 
specific ablation of TNF receptor 2 exacerbated macrophage-induced 
cardiomyocyte dysfunction. Specifically, upon attachment of TNFR2-1-
macrophages to WT myocytes, myocyte function significantly decreased from 
both baseline and WT HF macrophage attachment levels (2.80 :!:. 0.19 vs. 9.39 :!:. 





Figure 27: Attachment of wild type HF-derived macrophages imparts a significant dysfunction as 
compared to baseline cardiomyocyte function . Attachment of R1 -1- HF-derived macrophages 
improves this dysfunction as compared to WT HF-derived, and attachment of R2-1- HF-derived 
macro phages exacerbates the inflammatory cell derived dysfunction. 
Taken together these data provide the first known report delineating the role of 
inflammatory cell-specific TNF receptors on cardiomyocyte function in the in vitro 
co-cultured macrophage/myocyte functional model. Excitingly, these data 
corroborate our in vivo, whole animal data thereby further implicating unique TNF 
receptor-specific effects as central mediators of heart failure pathophysiology. 
Heart Failure-Derived Macrophages Stimulate Cardiomyocyte Free Radical 
Production 
While the presented data presented implicate TNF receptors as central 
mediators in the failing heart they do not uncover the mechanism by which this 
dysfunction occurs. As generation of free radicals has long been studied as a 
central and crucial underlying mechanism of cardiomyocyte dysfunction, we 
studied the production of myocyte ROS in our model. Specifically, we examined 
the immediate effects of macrophage attachment on the generation of oxygen 
free radicals within the cardiomyocyte. First, LPS-stimulated macrophages were 
co-cultured with DCF-Ioaded myocytes, and fluorescence was observed over the 
short-term. Macrophage attachment rapidly induced myocyte ROS generation 
within 15 minutes.{Figure 28) We then performed similar experiments with heart 
failure derived macrophages and DCF-Ioaded myocytes. As seen in Figure 30, 
analogous to the contractile responses, despite close cell-to-cell proximity, wild-
type heart failure derived macrophages did not significantly induce myocyte ROS 
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Figure 28: Attachment of wild type HF -<Jerived macro phages to wild type 
cardiomyocytes induces reactive oxygen species production in the 
cardiomyocyte 15 minutes post-attachment. 
rapid myocyte ROS generation with an increase in DCF fluorescence, as seen in 
the second row. In contrast, the increase in myocyte ROS was not evident with 
the attachment of macrophages derived from TNFR1 -1- heart failure mice, as 
seen in the third row . Finally, attachment of TNFR2-1- HF macrophages induced 
cardiomyocyte free radical production to the same degree as that induced by WT 
HF macro phages. Interestingly, increases in cardiomyocyte fluorescence 
occurred in close approximation to the sites of macrophage attachment, as seen 
in Figure 29, implying a direct, localized activation of the cardiomyocyte by the 
macrophage and not a more generalized effect. The group data, confirmed the 
qualitative images (Figure 31). DCF fluorescence was not significantly different 
from baseline with the attachment of macrophages from wild-type sham mice (-
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3.21 ±. 3.12) or with unattached wild-type heart failure macro phages (5.19 ±. 
3.675). However, attachment of wild-type heart failure macrophages significantly 
augmented myocyte ROS (31.25 ±. 7.92), which was abrogated with the loss of 
macrophage TNFR1 (4.85 ± 2.52) and similar upon loss of macrophage TNFR2 
(19.52 ± 6.94). Interestingly, additional stimulation of TNFR1-1- HF macrophages 
with LPS still did not result in significant production of ROS upon attachment to 
myocytes (1.857 ±. 0.60) indicating a TNFR1 inflammatory cell dependent 
mechanism involved in myocyte ROS production. Hence, heart failure-derived 
macrophages induced myocyte ROS in a juxtacrine and TNF receptor-dependent 
manner (Figure 31). These data represent the first known report implicating the 
role of inflammatory cell specific TNF receptor expression in the production of 
cardiomyocyte free radical production in heart failure. 
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Figure 29: Representative three dimensional computer generated color map 
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Figure 30: Representative brightfield and DCF fluorescent pictures of cardiomyocytes at 
baseline and 15 min post macrophage introduction. At top, WT HF paracrine interaction 
showed no effect on cardiomyocyte free radical production. Second, upon attachment of 
WT HF macrophages, myocyte free radical production drastically increased. Third , upon 
attachment of TNFRV HF macrophages, no significant change was seen. Bottom, upon 
attachment of TNFR2-1- HF macrophages, myocytes free radical production was elevated to 
a level equivalent to WT HF macrophage attachment. 
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Figure 31: Group quantitative data reveal that upon attachment of WT HF macrophages, a 
significant increase in fluorescence was observed (* p=O.0147) within the cardiomyocyte. This 
increase was present to an equivalent degree upon attachment of TNFR2-1- HF macrophages 
(p<O.05) but abolished upon attachment ofTNFR1 -1- macrophages (p=NS). 
Wild Type, TNFR1.f-, and TNFRZ1- Macrophages Attach to Myocytes in 
Equivalent Numbers 
Stimulation of the membrane TNF receptor has a myriad of downstream effects 
with one of the most important being the augmented production of several pro-
inflammatory cytokines including TNF. These inflammatory mediators, are also 
known modulators of cellular adhesion receptors and molecules. Hence, it is 
possible that alterations in macrophage-induced myocyte dysfunction was related 
to changes in the magnitude macrophage attachment. To investigate this, we 
obtained brightfield images at the initiation of macrophage/myocyte contact and 
15 minutes post-attachment. The numbers of attached macrophages was 
determined in the 15 minute post-attachment group and reported as the final 
number of attached macrophages. As can be seen in Figure 32 there was no 
significant difference in number of macrophages attached between either the 
WT, TNFR1-1·, or TNFR2-i- groups, thereby ruling out that these effects were 
related to greater or fewer macrophages attached to the myocyte. Interestingly, 
the average number of macrophages attached, four, has previously been 
reported in our lab in separate studies and suggests a possible "maximal upper 
limit" of macrophage load carrying ability by the cardiomyocyte. 
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Figure 32: Group data reveal no significant differences in number of 
macrophages attached to myocytes in WT, TNFR1 -1-, or TNFR2-1- groups (p=NS). 
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CONCLUSION 
This study demonstrates for the first time that activated macrophages, whether 
stimulated via LPS or by the HF state, induce contractile depression and 
oxidative stress in a juxtacrine, but not paracrine manner. In addition, this cell-to-
cell contact is dependent not only upon physical contact, but also on 
inflammatory cell TNF receptor signaling. Whereas TNFR1 augments the 
detrimental inflammatory cell-cardiomyocyte interaction, TNFR2 attenuates the 
contractile dysfunction but has no effect on ROS production. This suggests that 
analogous interactions could occur in human HF and that such juxtacrine, 
receptor dependent responses may represent a therapeutic target in patients. 
Upon physical attachment, activated macro phages enact detrimental cascades. 
Free radical production is immediately induced within the cardiomyocyte, which, 
in turn, leads to cardiomyocyte dysfunction. Whether this is the sole mechanism 
of dysfunction is still not completely defined; however, this work provides an 
important step in the quest for this answer. In support of this theory are reports 
that oxidant radicals inhibit cardiomyocyte contraction via interference with 
contractile proteins [101]. In order to fully elucidate this mechanism, future 
studies could be done using antioxidant pre-loaded cardiomyocytes. Overall, 
these data provide an exciting and important piece of the heart failure puzzle and 
suggest that modulation of immune cell, specifically macrophage, TNF receptor 
expression may be an important part of the complex pathological mechanism of 
the failing heart. 
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CHAPTER VI 
SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
Summary of Findings 
The significance of TNF and inflammation in the pathophysiology of myocardial 
dysfunction is not an uniformly accepted principle. While the preclinical data 
regarding the influence of TNF in HF has been overwhelmingly positive, in that 
antagonism of TNF in various animal models has shown significant protective 
effects, the clinical data has not been so promising. How could the preclinical 
and clinical experiments have such dichotomously opposing results? It is likely 
that TNF has more complex inter and intrace"ular effects than previously 
appreciated. Previous work in the Prabhu lab has delineated the dichotomous 
relationship of the TNF receptors in whole body knockout animals, in that TNFR1 
signaling appears detrimental and TNFR2 signaling, on some level beneficial. 
This study serves to unravel the mystery of TNF even further by determining the 
influence of inflammatory cell specific TNF receptor expression in HF physiology. 
The data demonstrated here indicates that modulation of the TNF receptors in 
the inflammatory compartment can have significant influence over the 
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pathological processes involved in post ischemic remodeling. Specifically, loss 
of TNFR1 in inflammatory cells demonstrated beneficial influences in cardiac 
remodeling and many of the deleterious processes that define the pathology of 
HF. Conversely, selective loss of TNFR2 in inflammatory cells did not 
significantly influence post-infarction cardiac remodeling, or inflammatory cell 
activation. 
Nonetheless, loss of either TNFR1 or TNFR2 in inflammatory cells improved 
post-infarction survival. This is interesting given that the loss of TNFR2 does not 
significantly change the phenotype observed in chronic HF. This is of further 
interest in that it correlates with previously reported data [63] that showed a 
similar survival benefit in TNFR1 and R2 whole body knockouts. 
We also delineated the importance of inflammatory cell and myocyte juxtracrine 
interactions in myocardial dysfunction and cellular damage. We developed a 
unique co-culture mechanism to study, in an in vitro manner, the interactions 
between isolated myocytes and activated macrophages. This technique allows 
for real time measurement of myocyte function and the generation of reactive 
oxygen species in response to interactions to macro phages. Using this method 
we determined that peritoneal macro phages activated by exposure to LPS 
elicited myocyte contractile dysfunction and ROS generation in a juxtacrine but 
not paracrine manner. This is interesting from two standpoints. First it shows 
that activated inflammatory cells can induce significant myocyte dysfunction. 
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Secondly, this interaction is dependent on cell-to-cell contact. This finding 
suggests that pro-inflammatory states in HF are more than just an 
epiphenomenon, and actively participate in myocardial dysfunction on the cellular 
level. Perhaps more interestingly, we found that HF derived macrophages 
produced a similar level of myocyte dysfunction as LPS-stimulated cells. 
Taking this one step further, we examined the selective role of TNF receptors in 
the macrophage-myocyte interactions. In line with our findings in the in vivo 
model, selective loss of the TNFR1 receptor in inflammatory cells resulted in less 
myocyte dysfunction and less ROS production than inflammatory cells 
possessing either both TNF receptors or those possessing only the TNFR1 
receptor. When considered in conjunction with the in vivo studies our finding 
demonstrates that the inflammatory cell serves as a significant source of myocyte 
dysfunction observed in HF and that, at least to some extent, direct cellular 
interactions between macrophages and myocytes are required for this effect to 
take place. This work demonstrates the fundamental role of the inflammatory cell 
in the pathophysiology of chronic HF, as well as the importance of TNF receptor 
signaling in mediating these effects. Selective modulation of the TNF receptors 
in the inflammatory compartment can yield dichotomous effects on cardiac 
remodeling and function following myocardial injury. We have demonstrated that 
inflammatory cell-localized TNFR1 exacerbates post-infarction remodeling in 
chronic HF and is required for myocardial pro-inflammatory cytokine generation. 
Conversely, inflammatory cell-localized TNFR2 yields modest beneficial effects. 
98 
Future Directions 
Heart failure is of paramount importance from a public health standpoint in the 
U.S., in terms of both patient lives and dollars spent. There are approximately 5 
million Americans living with clinically documented HF representing a large 
percentage of health care expenditure, many times for repeated admissions for 
the most decompensated patients. In fact, it is the number one Medicare 
discharge diagnosis. Many of these patients not only spend many of their last 
months or years in a downward spiral in and out of the hospital but also face a 
prognosis worse than many cancers. It is therefore of the utmost importance to 
develop new therapies to combat this malignant condition [100]. 
This study provides insights into the role of TNF in the failing heart. With the 
robust nature of the benefit demonstrated in animal models, it is hard to believe 
that some element of protection is not derived from modulation of TNF 
expression and signaling. Yet several clinical studies were overwhelmingly 
negative, showing completely opposite outcomes from those expected. As has 
been demonstrated in previous work in the Prabhu lab and now with this study, 
all TNF signaling is not equal, and the cellular interactions and signaling 
mechanisms at play are much more complicated than previously believed. 
Discovery of the harmful effects of TNFR1 signaling offer ripe ground to reopen 
the possibility of using TNF antagonism as a therapeutic approach to chronic HF. 
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The development of selective TNFR1 blocking agents in the future could serve to 
re-establish this potential mode of HF therapy. Other options along this line 
would be a method by which to negate sTNF, taking advantage of the differences 
in the two receptors, as TNFR1 binds both sTNF and mTNF and TNFR2 binds 
primarily mTNF. While this would not be as effective as a TNFR1 antagonist, it 
would help to switch the balance more in favor of TNFR2 signaling and hopefully 
improved clinical outcomes. 
From a more mechanistic standpoint, our understanding of the role of 
inflammation in chronic HF is still in its infancy, in that our understanding of the 
inflammatory compartment and its influence on other organ systems is increasing 
exponentially from day to day. The data in this study, while unique and 
groundbreaking, is an early and basic explanation of the interplay between 
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